FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference. This is an important step for Acurx, a great group of scientists to work with.
They will be presenting at the 33rd Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) this month. Specifically, a scientific poster entitled "Novel pharmacology and susceptibility of ibezapolstat against C. difficile isolates with reduced susceptibility to C. difficile-directed antibiotics" will be presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for microbiome aspects of our ibezapolstat clinical trial program.